Core Insights - Tempus AI and Doximity are prominent players in the Medical Information Systems industry, with Tempus focusing on precision medicine through AI and Doximity serving as a medical network for U.S. physicians [1][2] Company Overview Tempus AI - Tempus specializes in precision medicine, aggregating multimodal data from clinical care and laboratory testing to provide AI-enabled solutions [1] - The Diagnostics segment is a key growth driver, with revenues from profiling assays supporting therapy selection and disease monitoring, achieving a 111.5% year-over-year growth in 2025 [5][9] - The Data and Applications segment also saw significant growth, with a 30.9% year-over-year increase in sales [6] - Tempus is developing AI-driven clinical applications, including TIME and Next, to enhance patient matching and care pathway intelligence [7][10] Doximity - Doximity has a strong presence, reaching over 80% of U.S. physicians, with its AI tools experiencing over fivefold growth year over year [2][11] - The company reported a 10% revenue growth in fiscal Q3 2026, supported by user engagement, surpassing 3 million registered members [11][12] - Doximity's AI products are rapidly adopted, with over 300,000 prescribers using these tools, enhancing engagement and positioning for future revenue opportunities [12][13] Market Context - The global healthcare information systems market is projected to reach nearly $1,773.33 billion by 2034, attracting investor interest in this sector [3] - Over the past year, Tempus and Doximity's shares have declined by 10.2% and 58.1%, respectively [4] Financial Performance Tempus AI - The Zacks Consensus Estimate for Tempus indicates a loss per share of 34 cents for 2026, reflecting a 44.3% year-over-year improvement [14] - Tempus trades at a forward price-to-sales (P/S) ratio of 4.50X, which is lower than its median [16] Doximity - The Zacks Consensus Estimate for Doximity's fiscal 2026 earnings per share is projected at $1.54, indicating an 8.5% year-over-year growth [14] - Doximity's P/S ratio stands at 6.35X, also below its median [16] Investment Outlook - Tempus is positioned as a compelling player in diagnostics and AI-enabled healthcare innovation, despite uncertainties regarding the sustainability of its growth rates [17][18] - Doximity continues to show solid growth and user engagement, with a favorable outlook for unlocking additional revenue streams through product innovation [19]

Group 1 - Tempus AI, Inc. (NYSE:TEM) is recognized for its technology that organizes and analyzes clinical and molecular data to enhance personalized patient care [3] - The company's platform utilizes AI for diagnostic tests, matching patients with clinical trials, and aiding pharmaceutical companies in cancer treatment discovery [3] - Jim Cramer expressed a cautious outlook on TEM, indicating it is a high multiple stock in a sell-off influenced by oil prices and interest rates, suggesting it will continue to decline [1][2] Group 2 - There is a belief that while TEM has potential, other AI stocks may offer better upside potential with less downside risk [4] - The report suggests looking for undervalued AI stocks that could benefit from trends such as Trump-era tariffs and onshoring [4]

Group 1 - Tempus AI (TEM) has experienced a nearly 60% decline from its 52-week highs, presenting a favorable risk/reward scenario as the company continues to scale [1] - The company has established a strong competitive advantage through the integration of genomic sequencing [1] Group 2 - The article highlights the author's investment strategy, focusing on identifying underfollowed stocks with potential, inspired by Cornwall Capital's approach [1] - The author shares a successful investment experience with Opendoor Technologies, indicating a strategy of acquiring shares at lower prices before significant rallies [1] - The author is currently pursuing another investment opportunity with Gamesquare Holdings, encouraging others to explore this stock [1]

Core Insights - The ongoing conflict involving Iran is causing a significant rise in oil prices, which is negatively impacting stock markets and may lead to further losses ahead [1][2] - Historical trends indicate that oil shocks often result in bear markets, prompting a recommendation to raise cash to protect investments [2] - Despite the turmoil, there is a strong sentiment against tech stocks, with major companies like Meta, Microsoft, and NVIDIA facing heavy selling pressure [3] Company Insights - **Tempus AI, Inc. (NASDAQ:TEM)**: The stock is viewed as a decent speculative investment, but it is expected to decline further due to its high valuation in a challenging market environment. A recommendation is made to hold some shares but not all [7][8] - **Oscar Health, Inc. (NYSE:OSCR)**: The stock has recently decreased in value, presenting a buying opportunity. It is suggested to buy half of the desired position now and consider purchasing more if the price drops to $9. The leadership of CEO Mark Bertolini is viewed positively, influencing the bullish outlook on the stock [9][10]

Core Insights - Tempus AI (TEM) is expanding its presence in 2026 through strategic collaborations with pharmaceutical companies, healthcare institutions, and technology innovators to enhance data-driven insights for clinical outcomes and drug development [1] Group 1: Strategic Collaborations - Tempus has partnered with Daiichi Sankyo to accelerate the clinical development of an antibody drug conjugate (ADC) program in oncology, utilizing Tempus' PRISM2 AI models [2] - The company has integrated Median Technologies' eyonis LCS solution into the Tempus Pixel platform for non-invasive characterization of lung nodules, improving clinical decision-making [3] - A collaboration with Blood Cancer United aims to create a patient-centered registry for pediatric acute myeloid leukemia (pAML), leveraging Tempus' AI-enabled health concierge app and cloud-based analytics [4] - Tempus has formed a multi-year strategic collaboration with NYU Langone Health to enhance cancer care through advanced molecular profiling and data-driven insights [4] Group 2: Industry Updates - Guardant Health, Inc. has entered a multi-year collaboration with Merck to support the development of Merck's oncology portfolio using Guardant's Smart platform [5][6] - 10x Genomics, Inc. announced that a research consortium will utilize its Xenium spatial platform to create a comprehensive multimodal cancer dataset [7] - BioTuring and 10x Genomics have collaborated to streamline single-cell and spatial data analysis, enhancing analytical capabilities [8] Group 3: Stock Performance and Valuation - Tempus' shares have increased by 12.2% over the past year, contrasting with a 29.5% decline in the industry, while the S&P 500 has improved by 17.6% [9] - The current forward Price-to-Sales (P/S) ratio for TEM is 4.98X, lower than the industry median of 5.34X, indicating a relatively cheap valuation [11] - The loss per share estimate for 2026 has widened to 32 cents from 18 cents over the past 30 days [12]

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to reinvent customer experiences [1] - Elon Musk predicts that humanoid robots could create a market worth $250 trillion by 2040, reshaping the global economy [2] - Major firms like PwC and McKinsey recognize AI's potential to unlock multi-trillion-dollar opportunities [3] Industry Trends - The AI revolution is characterized by a powerful breakthrough that is redefining work, learning, and creativity, attracting significant interest from hedge funds and top investors [4] - A smaller, under-owned company is identified as holding the key to the AI revolution, suggesting a potential investment opportunity [4][6] - Billionaires and industry leaders, including Bill Gates and Warren Buffett, are positioning themselves around AI, indicating its importance and transformative potential [8] Investment Opportunities - There is a strong belief that the current market may overlook a specific stock that could become highly valuable in the future [9] - A detailed report is available that provides insights into a groundbreaking AI company, emphasizing its technology and growth potential [10]

Core Insights - Tempus AI (TEM) is positioned at the intersection of diagnostics, data, and artificial intelligence, focusing on a precision medicine platform to aid informed decision-making for healthcare professionals and researchers [1] Revenue Performance - In 2025, Tempus generated $1.27 billion in total revenues, with significant growth in both Diagnostics and Data and Applications segments [2] - Diagnostics accounted for $955.4 million, approximately 75% of total revenue, while Data and Applications contributed $316.4 million, or about 25% of total revenues [5][7] - Diagnostics revenues increased by 111.5% year-over-year, with a notable 121.6% growth in Q4 2025, driven by 29% growth in Oncology volume and 23% growth in Hereditary volume [6] Business Model and Offerings - Tempus aggregates multimodal data from clinical care and laboratory testing, utilizing AI to provide actionable insights for various stakeholders [3] - The company’s revenue model includes two main segments: Genomics, which focuses on oncology and hereditary testing, and Data and Services, which commercializes de-identified datasets and clinical trial services [4] Growth Drivers - The acquisition of Ambry Genetics in February 2025 enhanced Tempus's capabilities in inherited cancer risk testing and rare disease panels, contributing to revenue growth [6] - Data and Applications segment saw a 25.1% year-over-year revenue increase in Q4 2025, with Insights revenues growing by 69.5% [8] AI Applications and Regulatory Milestones - Tempus is developing AI applications beyond core testing, including tools for care gap identification and imaging platforms that integrate AI into diagnostic workflows [9][10] - The company has received regulatory clearances that support broader use cases, enhancing its positioning with life sciences partners [10] Investor Considerations - Key factors for investors include pricing and reimbursement progress, the conversion of contracted data value into recognized revenues, and the potential for operating leverage as adjusted EBITDA improves [12][13] - The company’s current Zacks Rank is 4 (Sell), indicating near-term earnings estimate trends, with growth durability and pricing gains being critical for future sentiment [14]

Core Insights - The drug discovery process is inefficient, requiring an average of 2,500 compounds and over four years to find one candidate for clinical trials [2][4] - Artificial intelligence (AI) is transforming drug discovery by analyzing large datasets and speeding up the identification of promising compounds [3] Company Summaries Recursion Pharmaceuticals - Recursion Pharmaceuticals has improved the drug discovery process, averaging 330 compounds synthesized in 17 months compared to the industry average [4] - The company utilizes a drug development operating system that integrates robotic labs, large biological datasets, and AI models, with proprietary datasets valued at $213 million from Roche and Genentech [5] - For full-year 2025, Recursion's revenue is projected at $74.7 million, with five clinical programs in progress and a cash runway extending into 2028 [6] - The company has demonstrated clinical proof-of-concept with a 43% median reduction in polyp burden for Familial Adenomatous Polyposis patients [6] Tempus AI - Tempus AI has developed a vast library of clinical and molecular data to enhance precision medicine, focusing on oncology, diagnostics, and genomics [8] - The company reported trailing revenue of $1.27 billion, growing approximately 30% annually, with a strong data engine driven by diagnostics [9] - Tempus is currently unprofitable with a net loss of $245 million, but analysts project nearly 30% annual revenue growth over the next three years [12] Industry Context - The healthcare industry in the U.S. is valued at $4.7 trillion, and advancements in AI could significantly change drug discovery and disease diagnosis [13] - Both Recursion Pharmaceuticals and Tempus AI are positioned to become integral parts of the evolving healthcare infrastructure [13][14]

Core Insights - Tempus AI, Inc. (NASDAQ:TEM) is recognized as one of the 10 Best New AI Stocks to Buy, indicating strong market interest and potential for growth [1] - Analysts have differing price targets for Tempus AI, with H.C. Wainwright raising it to $95 while Morgan Stanley lowered it to $70, reflecting varied outlooks on the company's future performance [3][4] - The company is focused on leveraging artificial intelligence in healthcare, particularly in precision medicine and diagnostics, positioning itself for significant long-term growth [4] Analyst Ratings - H.C. Wainwright analyst Yi Chen raised the price target for Tempus AI to $95 from $89 while maintaining a Buy rating, emphasizing the company's strategic partnerships [1] - Morgan Stanley adjusted its price target down to $70 from $85 but retained an Overweight rating, indicating confidence in the company's long-term growth despite the target reduction [3] Strategic Partnerships - Tempus AI has expanded its collaborations with major companies like Merck & Co. and Median Technologies, enhancing its capabilities in precision medicine and AI-driven diagnostics [1][3] - The collaboration with Merck & Co. specifically aims to accelerate biomarker discovery and support oncology research, further solidifying Tempus AI's strategic positioning in the healthcare sector [3] Company Overview - Tempus AI, founded by Eric Lefkofsky, utilizes large-scale data analytics to improve clinical and molecular data applications, aiming to enhance diagnostics and treatment decisions [4] - The integration of AI into clinical workflows within the healthcare industry positions Tempus AI favorably for future growth, making it an attractive investment opportunity [4]

Core Insights - Tempus AI (NASDAQ:TEM) is recognized as one of the top stocks to buy in Cathie Wood's 2026 Portfolio, leveraging AI to enhance patient treatment through data analysis [1] - The company has seen a significant increase in hedge fund interest, with 41 out of 1041 tracked hedge funds holding stakes in Tempus AI by the end of last year, up from 32 funds in September [1] - Tempus AI's stock has appreciated approximately 17% over the past year, driven by rising demand for its genomic testing and data tools [2] Financial Performance - In Q4, Tempus AI reported a revenue increase of over 80% year-over-year, with adjusted EBITDA turning positive [2] - The revenue outlook for 2026 indicates a growth rate of 25%, which, while slower than the previous year, still exceeds Wall Street's expectations [2] Market Position - Tempus AI's platform is now integrated with over 5,000 healthcare providers across the U.S., reflecting its expanding market presence [2]